ADA: Once-weekly cagrilintide + semaglutide promising in type 2 diabetes

Article excerpt

Three studies presented at the American Diabetes Association's annual meeting in New Orleans found that once-weekly cagrilintide combined with semaglutide significantly improved blood sugar control in adults with type 2 diabetes. The combination therapy worked for patients already taking metformin and basal insulin who weren't adequately controlled with diet and exercise alone. Published simultaneously in The Lancet Diabetes & Endocrinology and The Lancet, the research suggests the amylin receptor agonist could offer a new treatment option for this difficult-to-manage patient population.